Soligenix to Present at BIO CEO & Investor Conference

Core Viewpoint - Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs, and it will present at the BIO CEO & Investor Conference on February 10-11, 2025 [1]. Company Overview - Soligenix is developing HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and is seeking regulatory approvals following the successful completion of its second Phase 3 study [3]. - The company is also expanding its synthetic hypericin (SGX302) into psoriasis and developing dusquetide (SGX942) for inflammatory diseases, including oral mucositis in head and neck cancer, and SGX945 for Behçet's Disease [3]. - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine, and vaccines targeting filoviruses and COVID-19, utilizing the ThermoVax® heat stabilization technology [4]. Conference Participation - Registered attendees of the BIO CEO & Investor Conference can schedule one-on-one meetings with Soligenix management through the conference scheduling platform [2].